Cyclohexyl methacrylate

Repeated dose toxicity: oral

Administrative data

Endpoint:

sub-chronic toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2017-05-24 to 2017-10-17

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2018

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

Version / remarks:

29 Jul 2016

Deviations:

yes

Remarks:

Please refer to Principles of Method.

Test guideline 2

Qualifier:

according to guideline

Guideline:

OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)

Version / remarks:

21 Sep 1998

Deviations:

yes

Remarks:

Please refer to Principles of Method.

Principles of method if other than guideline:

The duration of treatment covered a 10 weeks premating period and 2 weeks mating period in both sexes, approximately 3 weeks postmating in males, and the entire gestation period as well as 21 days of lactation and up to 15 days postweaning, or 38 days postmating for sperm negative females.
In addition groups of 10 males and 10 females, selected from F1 pups to become F1 rearing animals, were treated with the test substance at doses of 0, 100, 300 and 1000 mg/kg bw/d postweaning until puberty.

GLP compliance:

yes (incl. QA statement)

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Cyclohexyl methacrylate

EC Number:

202-943-5

EC Name:

Cyclohexyl methacrylate

Cas Number:

101-43-9

Molecular formula:

C10H16O2

IUPAC Name:

cyclohexyl 2-methylprop-2-enoate

Specific details on test material used for the study:

SOURCE OF TEST MATERIAL
- Batch No.of test material: 010545EDA0
- Expiration date of the lot/batch: Jan 2018

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: refrigerator, avoid temperatures > 35 °C

Test animals

Species:

rat

Strain:

Wistar

Remarks:

Crl:WI(Han)

Details on species / strain selection:

The test guidelines require the rat to be used as the animal species. This rat strain was selected since extensive historical control data are available for Wistar rats.

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 36 +/- 1 days
- Weight at study initiation: males: 118.4-142.6 g, females: 92.7-124.3 g
- Fasting period before study: no
- Housing: as groups of 4 in Polysulfonate cages supplied by TECHNIPLAST, Hohenpeißenberg, Germany and Becker & Co., Castrop-Rauxel, Germany with exceptions: during overnight matings, male and female mating partners were housed together in Polycarbonate cages type III (same supplier) and pregnant animals and their litters were housed together until PND 21 in Polycarbonate cages type III. Pregnant females were provided with nesting material (cellulose wadding) toward the end of gestation. For enrichment wooden gnawing blocks (Typ Lignocel® block large, J. Rettenmaier & Söhne
GmbH + Co KG, Rosenberg, Germany) were added. In addition in Polysulfonate cages large play tunnels (Art. 14153; supplied by PLEXX B.V., Elst, Netherlands) were added.
- Diet: ad libitum, ground Kliba maintenance diet mouse/rat "GLP", Provimi Kliba SA, Kaiseraugst, Switzerland
- Water: ad libitum, drinking water
- Acclimation period: 8 days

DETAILS OF FOOD AND WATER QUALITY:
The food used in the study was assayed for chemical and for microbiological contaminants. The diet was found to be suitable. The concentration of microorganisms did not exceed 1*10^5/g feed.
The drinking water is regularly assayed for chemical contaminants as well as for the presence of (pathogenic) microorganisms by the municipal authorities of Frankenthal and the Environmental Analytics Water/Steam Monitoring of BASF SE. The drinking water was found to be suitable.
The bedding and the enrichment is regularly assayed for contaminants (chlorinated hydrocarbons and heavy metals) by the producer. It was found to be suitable.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:

oral: gavage

Details on route of administration:

The oral route was selected since administration by gavage has been proven to be appropriate for the detection of a toxicological hazard.

Vehicle:

water

Remarks:

drinking water (with 10 mg/ 100 mL Cremophor EL)

Details on oral exposure:

PREPARATION OF DOSING SOLUTIONS:
For the preparation of the administration suspensions the test substance was weighed in a calibrated beaker depending on the dose group, topped up with drinking water with 10 mg/100 mL Cremophor EL and intensely mixed with a magnetic stirrer. During administration, the preparations were kept homogeneous with a magnetic stirrer.

VEHICLE
- Concentration in vehicle: 0, 1, 3 and 10 g/100 mL
- Amount of vehicle: 10 mL/kg bw

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

Analytical verifications of the stability of the test substance in drinking water + 10 mg/100 mL Cremophor EL for a period of 7 days at room temperature were carried out prior to the start of the study.
At the beginning and at the end of premating, once during gestation and once during lactation of the study each 3 samples were taken from the lowest and highest concentration for potential homogeneity analyses. The 3 samples were withdrawn from the top, middle and bottom of the preparation vessel. These samples were used as a concentration control at the same time. At the above mentioned time points additionally one sample from the mid concentration was taken for concentration control analysis. Of each sample, one additional reserve sample was retained.
The samples collected at the beginning of the administration period and during lactation period were analyzed. The remaining samples were stored at -20 °C.

Results:
The stability of test substance in drinking water + 10 mg/100 mL Cremophor EL was demonstrated for a period of 7 days at room temperature.
The homogeneous distribution of the test substance in drinking water + 10 mg/100 mL Cremophor EL was demonstrated.
Measured values for the test item were in the expected range of the target concentrations (90 - 110 %), demonstrating the correctness of the preparations. Measured values of samples 30 - 32 were slightly under the specification limit of 90 % (average 88.7 %), however, the re-check using the retain samples 30R-32R proved to be within the specification limits of 90-110 % (average 92.2 %).

Duration of treatment / exposure:

Animals of parental generation were treated for:
females: 126/133 days
males: 109/110 days

The duration of treatment covered a 10 weeks premating period and 2 weeks mating period in both sexes, approximately 3 weeks postmating in males, and the entire gestation period as well as 21 days of lactation and up to 15 days postweaning, or 38 days postmating for sperm negative females.

Frequency of treatment:

once daily, 7 days per week, exception: no administration to animals being in labor

Doses / concentrations

Doses / concentrations 1

Dose / conc.:

0 mg/kg bw/day (nominal)

Doses / concentrations 2

Dose / conc.:

100 mg/kg bw/day (nominal)

Doses / concentrations 3

Dose / conc.:

300 mg/kg bw/day (nominal)

Doses / concentrations 4

Dose / conc.:

1 000 mg/kg bw/day (nominal)

No. of animals per sex per dose:

12 parental animals

Control animals:

yes, concurrent vehicle

Details on study design:

- Dose selection rationale: Doses were selected based on request of the sponsor.

Positive control:

No positive control conducted.

Examinations

Observations and examinations performed and frequency:

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: During the administration period all animals were checked daily for any signs of morbidity, pertinent behavioral changes and signs of overt toxicity before the administration as well as within 2 hours and within 5 hours after the administration. Abnormalities and changes were documented daily for each animal.

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Detailed clinical observations were performed in all animals once prior to the first administration (day 0) and at weekly intervals thereafter.
- Detailed clinical observations checked in table No.1 were included.

BODY WEIGHT: Yes
- Time schedule for examinations: Body weight of the male and female parental animals was determined once a week at the same time of the day (in the morning) until sacrifice. During the mating period the parental females were weighed on the day of positive evidence of sperm (GD 0) and on GD 7, 14 and 20. Females with litter were weighed on the day after parturition (PND 1) and on PND 4, 7, 10 and 13.

FOOD CONSUMPTION AND COMPOUND INTAKE:
Food consumption was determined once a week for male and female parental animals. Food consumption was not determined after the 10th premating week (male parental animals) and during the mating period (male and female parental animals). Food consumption of the females with evidence of sperm was determined on gestation days (GD) 0-7, 7-14, and 14-20. Food consumption of females which gave birth to a litter was determined on PND 1-4, 4-7, 7-10 and 10-13.

WATER CONSUMPTION AND COMPOUND INTAKE: No

OPHTHALMOSCOPIC EXAMINATION: Yes, as part of the detailed neurological examination.

HAEMATOLOGY: Yes
- Time schedule for collection of blood: males: at termination, females: at PND 14
- Anaesthetic used for blood collection: Yes, isoflurane
- How many animals: in the first 10 surviving parental males (fasted) per group and a maximum of 10 females (fasted) with litters (in order of delivery) per group
- Parameters checked in table No.5 were examined.

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: males: at termination, females: at PND 14
- Animals fasted: Yes
- How many animals: in the first 10 surviving parental males per group and a maximum of 10 females with litters (in order of delivery) per group
- Parameters checked in table No.6 were examined.

URINALYSIS: Yes, as part of detailed clinical observations.

NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: end of administration period
- Dose groups that were examined: all, first 5 parental males and the first 5 females with litter (in order of delivery) per group
- Battery of functions tested are checked into table No. 2-4. In addition motor activity was determined in the dark using the TSE Labmaster System (TSE Systems GmbH, Bad Homburg, Germany) with 18 infrared beams per cage. The numbers of beam interrupts were counted over 12 intervals, each lasting 5 minutes.

IMMUNOLOGY: No

OTHER: Thyroid hormones
Blood samples for T4 and TSH were collected from retrobulbar venous plexus under isoflurane anesthesia.
- Time schedule for collection: from all dams at PND 14 and all males at termination, animals were fastened
- Dose groups that were examined: all males

Sacrifice and pathology:

GROSS PATHOLOGY: Yes. All parental animals were sacrificed by decapitation under isoflurane anesthesia. The exsanguinated animals were necropsied and assessed by gross pathology.

Organ weights: Were determined as listed in table No. 7.

HISTOPATHOLOGY: Yes. The organs or tissues of all parental animals were fixed in in 4% neutral-buffered formaldehyde or in modified Davidson’s solution as listed in table No. 8. Fixation was followed by histotechnical processing, examination by light microscopy and assessment of findings.

Other examinations:

Furthermore observations and examinations concerning estrous cycle, male reproduction, female reproduction and delivery and litter/pups were conducted. The details on those determinations are provided in IUCLID section 7.8.1.

Statistics:

Means and standard deviations were calculated.
Further statistics were performed as listed in table No. 9.

Results and discussion

Results of examinations

Clinical signs:

effects observed, treatment-related

Description (incidence and severity):

All male and all female animals of the mid- and high-dose groups (300 and 1000 mg/kg bw/d) showed salivation at least on one occasion during the treatment period. Individual males (three) of the low-dose group occasionally showed salivation during the mating and postmating periods. Due to salivation several male and female animals of the high- and mid-dose groups showed red discolored fur in the mouth or nose region during the treatment.
The temporary salivation and discolored fur was considered to be test substance-induced. From the temporary, short appearance of salivation immediately after dosing it is likely, that these findings were induced by a bad taste of the test substance or local affection of the upper digestive tract. It is, however, not considered to be an adverse toxicologically relevant finding.
No other clinical signs or changes of general behavior, which may be attributed to the test substance, were detected in any of the male and female F0 parental animals in any of the groups (01 - 03 , 100, 300 and 1000 mg/kg bw/d) during the study.
There were sporadic findings in individual F0 animals as follows:
One high-dose male animal (No. 43) showed protruding eyeball during mating days 4 - 14 and postmating days 0 - 22. One mid-dose male animal (No. 27) showed hyperthermia and sparse fur (grade: severe) during mating days 1 - 14 and during postmating days 0 - 2 and 0 - 21, respectively. One sperm positive high-dose female (No. 138) and one sperm negative middose female (No. 136) did not deliver F1 pups. None of these findings is considered to be treatment-related.

Mortality:

mortality observed, non-treatment-related

Description (incidence):

There were no test substance-related mortalities in any of the groups.
One F0 female of test group 03 (1000 mg/kg bw/d) showed piloerection and vaginal discharge (light yellow) on GD 19 and was found dead on GD 20. Histopathology revealed a marked inflammation of the placenta. This was considerd to be a spontaneous finding.

Body weight and weight changes:

effects observed, non-treatment-related

Description (incidence and severity):

Mean body weights and body weight change of all male and female F0 generation parental animals in all test substance-treated groups were comparable to the concurrent control during the entire study period.
The statistically significantly lower body weight change in the mid-dose males during premating days 63 – 70, the statistically significantly higher body weight change in the mid-dose females during premating days 38 - 35 as well as significantly higher body weight change in the mid and high-dose females during PND 0 - 21 were considered as spontaneous in nature and not as treatment related.

Food consumption and compound intake (if feeding study):

no effects observed

Description (incidence and severity):

Food consumption of all test substance-treated F0 male and female animals (100, 300 and 1000 mg/kg bw/d) was not influenced by the treatment throughout the entire study period.

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

effects observed, non-treatment-related

Description (incidence and severity):

No test substance related findings were observed.
One high-dose male animal (No. 43) showed protruding eyeball during mating days 4 - 14 and postmating days 0 - 22. In the pupillary reflex test one out of 5 examined male animals of dose group 01 and two out of 5 examined male animals of dose group 03 showed a retarded adaption of the pupil to light. These findings were regarded as spontaneous findings.

Haematological findings:

effects observed, treatment-related

Description (incidence and severity):

At the end of the administration period in males of test group 03 (1000 mg/kg bw/d) red blood cell (RBC) counts and hematocrit values were slightly, but significantly decreased.
Additionally, in males of test group 03 (1000 mg/kg bw/d) absolute eosinophil cell counts were slightly lower compared to controls, but this was the only changed differential blood cell fraction and therefore this alteration was regarded as treatment-related, but not adverse (ECETOC Technical Report No. 85, 2002). In females of test group 03 (1000 mg/kg bw/d) at lactation day 14, absolute and relative neutrophil counts were significantly lower and relative lymphocyte counts were significantly higher compared to controls. No changes among the total white blood cell (WBC) counts and other hematology parameters occurred in these individuals. Therefore, these alterations were regarded as treatment-related but not adverse (ECETOC Technical Report No. 85, 2002).
In males of test groups 02 and 03 (300 and 1000 mg/kg bw/d) after the administration period, prothrombin time (Hepatoquick’s test, HQT) was significantly reduced, but the values were within the historical control range (males, HQT 34.6-40.2 sec). Therefore, this change was regarded as incidental and not treatment-related.

Clinical biochemistry findings:

effects observed, treatment-related

Description (incidence and severity):

After the administration period in males of test group 03 (1000 mg/kg bw/d), total protein and globulin values as well as cholesterol and potassium values were significantly increased.
After lactation day 14 in females of test group 03 (1000 mg/kg bw/d) also total protein and globulin levels as well as albumin values were significantly higher compared to controls. Additionally, in females of test group 03 (1000 mg/kg bw/d) creatinine values were significantly lower compared to controls.

Urinalysis findings:

effects observed, treatment-related

Description (incidence and severity):

No treatment-related, adverse changes among urinalysis parameters were observed.
After the administration period in males of test groups 02 and 03 (300 and 1000 mg/kg bw/d), urine pH values were significantly decreased whereas urine specific gravity was significantly increased. Additionally, in males of test group 03 (1000 mg/kg bw/d) incidences of ketone bodies were significantly higher compared to controls. No hint of a dysregulation of the energy metabolism (e.g. changes in serum glucose, creatinine, triglycerides) was observed among these individuals. It can be assumed, that acidic metabolites of the compound are excreted via the urine decreasing the urine pH and maybe increasing the urine specific gravity. Methacrylic acid as metabolite of the compound is further degraded to Acetyl-CoA, and high abundance of this molecule results in formation of acetoacetate as ketone body, which is excreted via the urine (Greim et al., 1995). These changes are significant only in males, because metabolism rate is normally higher in this sex. Therefore, the mentioned altered urine parameters in males of test groups 02 and 03 are regarded as treatment-related, but not as adverse.

Behaviour (functional findings):

effects observed, treatment-related

Description (incidence and severity):

No test substance-related or spontaneous findings were observed in male and female animals of all test groups during the home cage observation.

The open field observations did not reveal any test substance-related findings in F0 male and female animals of test groups 01 and 02.
Three out of 5 examined male animals of dose group 03 (1000 mg/kg bw/d) showed slight salivation (area around the mouth was moist), which was considered to be treatment-related.

There were no test substance-related findings in male and female F0 animals of all test groups in sensorimotor tests/reflexes.
In the pupillary reflex test one out of 5 examined male animals of dose group 01 and two out of 5 examined male animals of dose group 03 showed a retarded adaption of the pupil to light. One out of 5 examined male animals of dose groups 02 and 03, respectively, showed very frequent vocalizations when touched. These were regarded as spontaneous findings.

No test substance-related impaired quantitative parameters were observed in male and female animals of all test groups.
As there was no dose-response the statistically significantly lower values of grip strength of forelimbs in females of dose group 01 was considered as spontaneous in nature and not treatment-related.

No statistically significant changes on motor activity data (summation of all intervals) was observed in all male and female animals of all dose groups in comparison to the concurrent control group.

Immunological findings:

not examined

Organ weight findings including organ / body weight ratios:

effects observed, treatment-related

Description (incidence and severity):

Absolute weights:
Mean absolute weights significantly increased are shown in table 10.
The terminal body weight of male animals was slightly decreased without statistical significance in test group 02 (by 4 %) and test group 03 (by 7 %).
All other mean absolute weight parameters did not show significant differences when compared to the control group 00.

Relative weights
Mean relative organ weights significantly increased or decreased are shown in table 11.
All other mean relative weight parameters did not show significant differences when compared to the control group 00.
The increase in absolute and relative liver and kidney weights in test group 03 male and female animals was considered to be treatment-related, but the kidney weight changes were considered as non-adverse.
The increase in relative adrenal and pituitary gland weights in test group 03 males and relative liver weights in test group 02 males was regarded as incidental and possibly secondary to the decreased terminal body weights in these groups. Additionally, weights were within historical controls for studies carried out according to the OECD 422 guideline (adrenal historical controls absolute/relative: 59.4-77.4 mg/ 0.016- 0.021 %, this study test group 03 absolute 65 mg, relative 0.018 %; liver historical controls relative 2.108-2.45 %, this study 2.423 %.).
Pituitary gland weights were compared with historical controls for studies carried out according to the OECD 408 guideline - as these values are not normally measured in studies carried out according to the OECD 422 guideline (pituitary gland historical controls absolute/relative: 7.8- 15.2 mg/0.002-0.004 %, this study 9.167 mg/0.003 %).
The decreased relative organ weights of the spleen in test group 01 male animals was regarded as incidental as there was no dose response and no significant histopathological changes in test group 03. The increased spleen weights of test group 03 males were due to the infiltration by lymphoma cells in the spleen of animal 41 (absolute spleen weight of animal 41: 2.94 g, while the other animals of this group showed weights around 0.6 g).

Gross pathological findings:

effects observed, non-treatment-related

Description (incidence and severity):

All findings occurred individually. They were considered to be incidental or spontaneous in origin and without any relation to treatment.

Neuropathological findings:

not examined

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Description (incidence and severity):

Treatment-related findings were observed in in the liver in female animals of test group 03.
In female animals, minimal hepatocellular hypertrophy was noted in the liver, with incidences and grading according to the table 12.
In male animals, minimal follicular hypertrophy/hyperplasia was noted in the thyroid gland, with incidences and grading according to the table 13.

In females, the predominant pattern of hepatocellular hypertrophy was centrilobular, the animal showing the periportal pattern was the premature decedent (female animal 137), where the liver was markedly enlarged even on gross evaluation. This was the only animal examined during pregnancy, therefore this possibly confounding factor should be taken into account and the relationship to treatment of the observed periportal hypertrophy is questionable.

The findings observed in the thyroid gland in male animals of test group 03 were finally considered as secondary in nature due to the observed functional liver effects and thus, as not adverse.

All other findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment.

Histopathological findings: neoplastic:

effects observed, non-treatment-related

Description (incidence and severity):

One male animal of test group 03 (animal No. 41) showed a lymphoma, this was assessed as incidental, as the occurrence of lymphoma has been documented in single control animals of this age in this laboratory.

Other effects:

no effects observed

Description (incidence and severity):

Furthermore results concerning estrous cycle, male reproduction, female reproduction and delivery and litter/pups are provided in IUCLID section 7.8.1.

Thyroid hormones:
In parental males (test groups 01, 02 and 03; 100, 300 and 1000 mg/kg bw/d) no treatment-related alterations of T4 and TSH levels were observed.

Effect levels

Key result

Dose descriptor:

NOAEL

Effect level:

300 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

clinical biochemistry

haematology

organ weights and organ / body weight ratios

Target system / organ toxicity

Key result

Critical effects observed:

yes

Lowest effective dose / conc.:

1 000 mg/kg bw/day (nominal)

System:

hepatobiliary

Organ:

liver

Treatment related:

yes

Dose response relationship:

yes

Relevant for humans:

not specified

Any other information on results incl. tables

Table No. 10 Absolute organ weights

When compared with control group 00 (=100%), the following mean absolute weights were significantly increased in test group 03:

	Male animals			Female animals
Test group (mg/kg bw/d)	1 (100)	2 (300)	3 (1000)	1 (100)	2 (300)	3 (1000)
Terminal body weight	101 %	96 %	93 %	101 %	102 %	100 %
Liver	99 %	101 %	123 %**	101 %	108 %	122 %**
Kidney	94 %	94 %	113 %**	104 %	105 %	117 %**

*p ≤ 0.05; **p ≤ 0.01

 

Table No. 11 Relative organ weight

When compared with control group 00 (=100%), the following mean relative organ weights were significantly increased or decreased in one or more test groups:

	Male animals			Female animals
Test group (mg/kg bw/d)	1 (100)	2 (300)	3 (1000)	1 (100)	2 (300)	3 (1000)
Adrenal glands	103 %	106 %	123 %**	-	-	-
Kidneys	93 %	97 %	120 %**	102 %	102 %	117 %**
Liver	98 %	105 %**	131 %**	100 %	105 %	122 %**
Pituitary gland	102 %	105 %	114 %**	-	-	-
Spleen	86 %*	91 %	127 %	-	-	-

*p ≤ 0.05; **p ≤ 0.01

 

Table No. 12 Histopathology

Liver	Female animals
Test group (mg/kg bw/d)	0 (control)	1 (100)	2 (300)	3 (1000)
No. of animals	12	12	12	12
Hypertrophy, centrilobular	0	0	0	3
Grade 1				3
Hypertrophy, peripheral	0	0	0	1
Grade 2				1

 

Table No. 13 Histopathology

Thyroid gland	Male animals
Test group (mg/kg bw/d)	0 (control)	1 (100)	2 (300)	3 (1000)
No. of animals	12	12	12	12
Hypertrophy/hyperplasia, follicular	0	0	0	2
Grade 1				2

 

DISCUSSION

In this Modified Combined Repeated Dose Toxicity Study with the Reproduction/ Developmental Toxicity Screening Test (OECD 422/408), the test substance cyclohexyl methacrylate was administered daily as an aqueous preparation to groups of 12 male and 12 female Wistar rats (F0 animals) by gavage at doses of 100, 300 and 1000 mg/kg body weight/day (mg/kg bw/d) to screen for potential repeated dose, reproductive and developmental toxicity. The informative value of the OECD 422 test was increased by a longer premating treatment period (10 weeks) and a postweaning follow-up of selected offspring until puberty.

Analyses confirmed the overall accuracy of the prepared concentrations and the homogeneity of the test substance in the vehicle. The stability of these preparations was demonstrated over a period of 7 days under ambient conditions.

The majority of male and female F0 animals in test groups 3 and 2 (1000 mg/kg bw/d and 300 mg/kg bw/d) showed salivation for a time period after gavage treatment. Secondary to salivation several male and female animals of these test groups showed red discolored fur in the mouth or nose region during the treatment. From the temporary, short appearance of salivation immediately after dosing it is likely, that this finding was induced by a bad taste of the test substance or local affection of the upper digestive tract. As such, this local finding was not considered to be an adverse and systemic-toxicologically relevant effect. While occasional salivation was the only notable finding during detailed clinical observations, no abnormalities were noted in FOB or motor activity measurements.

Food consumption and body weights/body weight gain remained unaffected in all treatment groups in F0 parents.

Dysregulation of the liver cell metabolism was detected in males and females treated with 1000 mg/kg bw/d, which was seen as increase of serum total protein and globulin values (males and females), increase of cholesterol and potassium levels (males) and high albumin level and low creatinine values (females). Additionally a marginal anemia was observed because of decreased red blood cell (RBC) counts and hematocrit values. Furthermore the liver showed a marked weight increase in animals of both sexes treated with 1000 mg/kg bw/d. A corresponding histopathological correlate in the form of hepatocellular centrilobular hypertrophy could only be detected in female rats. No further adverse or primary substance-related effects were detected in animals at 1000 mg/kg bw/d. At 100 and 300 mg/kg bw/d no test substance-related adverse findings were determined.

CONCLUSION

Under the conditions of the present modified OECD 422 combined repeated dose toxicity study with the reproductive/developmental screening test in Wistar rats, the NOAEL (no observed adverse effect level) for general, systemic toxicity of cyclohexyl methacrylate was 300 mg/kg bw/d for male and female rats, based on functional liver impairment in F0 parental rats at 1000 mg/kg.